Phytoestrogens/insoluble fibers and colonic estrogen receptor β: randomized, double-blind, placebo-controlled study.

AIM To assess the safety and effect of the supplementation of a patented blend of dietary phytoestrogens and insoluble fibers on estrogen receptor (ER)-β and biological parameters in sporadic colonic adenomas. METHODS A randomized, double-blind placebo-controlled trial was performed. Patients scheduled to undergo surveillance colonoscopy for previous sporadic colonic adenomas were identified, and 60 eligible patients were randomized to placebo or active dietary intervention (ADI) twice a day, for 60 d before surveillance colonoscopy. ADI was a mixture of 175 mg milk thistle extract, 20 mg secoisolariciresinol and 750 mg oat fiber extract. ER-β and ER-α expression, apoptosis and proliferation (Ki-67 LI) were assessed in colon samples. RESULTS No adverse event related to ADI was recorded. ADI administration showed a significant increases in ER-β protein (0.822 ± 0.08 vs 0.768 ± 0.10, P = 0.04) and a general trend to an increase in ER-β LI (39.222 ± 2.69 vs 37.708 ± 5.31, P = 0.06), ER-β/ER-α LI ratio (6.564 ± 10.04 vs 2.437 ± 1.53, P = 0.06), terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (35.592 ± 14.97 vs 31.541 ± 11.54, P = 0.07) and Ki-67 (53.923 ± 20.91 vs 44.833 ± 10.38, P = 0.07) approximating statistical significance. A significant increase of ER-β protein (0.805 ± 0.13 vs 0.773 ± 0.13, P = 0.04), mRNA (2.278 ± 1.19 vs 1.105 ± 1.07, P < 0.02) and LI (47.533 ± 15.47 vs 34.875 ± 16.67, P < 0.05) and a decrease of ER-α protein (0.423 ± 0.06 vs 0.532 ± 0.11, P < 0.02) as well as a trend to increase of ER-β/ER-α protein in ADI vs placebo group were observed in patients without polyps (1.734 ± 0.20 vs 1.571 ± 0.42, P = 0.07). CONCLUSION The role of ER-β on the control of apoptosis, and its amenability to dietary intervention, are supported in our study.

[1]  O. A. Martins,et al.  Variations in maternal care alter corticosterone and 17beta-estradiol levels, estrous cycle and folliculogenesis and stimulate the expression of estrogen receptors alpha and beta in the ovaries of UCh rats , 2011, Reproductive biology and endocrinology : RB&E.

[2]  F. Bazzoli,et al.  Chemoprevention of colorectal cancer: a role for ursodeoxycholic acid, folate and hormone replacement treatment? , 2011, Best practice & research. Clinical gastroenterology.

[3]  M. Barone,et al.  ERβ expression in normal, adenomatous and carcinomatous tissues of patients with familial adenomatous polyposis , 2010, Scandinavian journal of gastroenterology.

[4]  R. Agarwal,et al.  Chemoprevention of intestinal tumorigenesis in APCmin/+ mice by silibinin. , 2010, Cancer research.

[5]  G. Ingravallo,et al.  Dietary-induced ERbeta upregulation counteracts intestinal neoplasia development in intact male ApcMin/+ mice. , 2010, Carcinogenesis.

[6]  S. Hegazy,et al.  Evidences for antiosteoporotic and selective estrogen receptor modulator activity of silymarin compared with ethinylestradiol in ovariectomized rats. , 2010, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[7]  R. Leong,et al.  Sex differences in epidemiological, clinical and pathological characteristics of colorectal cancer , 2010, Journal of gastroenterology and hepatology.

[8]  S. Gruber,et al.  Use of hormone replacement therapy and the risk of colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Agarwal,et al.  Silibinin Inhibits Established Prostate Tumor Growth, Progression, Invasion, and Metastasis and Suppresses Tumor Angiogenesis and Epithelial-Mesenchymal Transition in Transgenic Adenocarcinoma of the Mouse Prostate Model Mice , 2008, Clinical Cancer Research.

[10]  J. Carrier,et al.  Estrogen receptor β deficiency enhances small intestinal tumorigenesis in ApcMin/+ mice , 2008, International journal of cancer.

[11]  S. Marangi,et al.  ER-β expression in large bowel adenomas: Implications in colon carcinogenesis , 2008 .

[12]  K. Dahlman-Wright,et al.  Review Nuclear Receptor Signaling | The Open Access Journal of the Nuclear Receptor Signaling Atlas Estrogen receptor β: an overview and update , 2022 .

[13]  H. Boshuizen,et al.  Plasma enterolignan concentrations and colorectal cancer risk in a nested case-control study. , 2007, American journal of epidemiology.

[14]  E. Feskens,et al.  Relation between plasma enterodiol and enterolactone and dietary intake of lignans in a Dutch endoscopy-based population. , 2007, The Journal of nutrition.

[15]  B. Aggarwal,et al.  Anticancer potential of silymarin: from bench to bed side. , 2006, Anticancer research.

[16]  J. Frasor,et al.  Impact of Estrogen Receptor β on Gene Networks Regulated by Estrogen Receptor α in Breast Cancer Cells , 2006 .

[17]  Shin-Da Lee,et al.  Apoptotic effects of over-expressed estrogen receptor-beta on LoVo colon cancer cell is mediated by p53 signalings in a ligand-dependent manner. , 2006, The Chinese journal of physiology.

[18]  J. Gustafsson,et al.  Estrogen receptors alfa (ERα) and beta (ERβ) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11 , 2005, Oncogene.

[19]  M. Wargovich,et al.  Modulation of aberrant crypt foci and apoptosis by dietary herbal supplements (quercetin, curcumin, silymarin, ginseng and rutin). , 2005, Carcinogenesis.

[20]  V. Speirs,et al.  Loss of expression of oestrogen receptor beta in colon cancer and its association with Dukes' staging. , 2005, Oncology reports.

[21]  H. Jarry,et al.  Silymarin is a selective estrogen receptor β (ERβ) agonist and has estrogenic effects in the metaphysis of the femur but no or antiestrogenic effects in the uterus of ovariectomized (ovx) rats , 2003, The Journal of Steroid Biochemistry and Molecular Biology.

[22]  A. Papavassiliou,et al.  Oestrogen receptor beta (ERbeta) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour's dedifferentiation. , 2003, European journal of cancer.

[23]  M. Barone,et al.  Distribution of Estrogen Receptor Subtypes, Expression of Their Variant Forms, and Clinicopathological Characteristics of Human Colorectal Cancer , 2002, Digestive Diseases and Sciences.

[24]  F. Gannon,et al.  Human estrogen receptor-α: regulation by synthesis, modification and degradation , 2002, Cellular and Molecular Life Sciences CMLS.

[25]  Takuji Tanaka,et al.  Dietary Conjugated Linolenic Acid Inhibits Azoxymethane‐induced Colonic Aberrant Crypt Foci in Rats , 2002, Japanese journal of cancer research : Gann.

[26]  P. Albert,et al.  Hormone replacement therapy and colorectal adenoma recurrence among women in the Polyp Prevention Trial. , 2001, Journal of the National Cancer Institute.

[27]  A. Di Leo,et al.  Estrogens and colorectal cancer. , 2001, Current drug targets. Immune, endocrine and metabolic disorders.

[28]  B. O’Malley,et al.  Proteasome-dependent degradation of the human estrogen receptor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[29]  M. Barone,et al.  Nuclear and cytosolic estrogen receptors in human colon carcinoma and in surrounding noncancerous colonic tissue. , 1987, Gastroenterology.

[30]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.

[31]  H. Adlercreutz,et al.  Dietary lignins are precursors of mammalian lignans in rats. , 2004, The Journal of nutrition.

[32]  I. J. Lynch,et al.  Expression of estrogen receptor (ER) subtypes and ERbeta isoforms in colon cancer. , 2001, Cancer research.